Newsroom
Featured News
- Business06 January 2026
Lotus Pharmaceutical Secures First Southeast Asian Approval for VAZKEPA® (Icosapent Ethyl) in Singapore
- Charity29 December 2025
Lotus Pharmaceutical Supports Street Medicine Program to Expand Access to Care for Those Most In Need
- Investors10 December 2025
Lotus Reports November 2025 Revenue of NT$1,059 Million
- Business03 December 2025
Alvogen US Acquisition Completed; Lotus Strengthens Global Specialty Pharma Platform
- Business01 December 2025
LENZ Therapeutics Announces MFDS Submission of New Drug Application for LNZ100 (VIZZ™) in South Korea for the Treatment of Presbyopia
- Business24 November 2025
Taiwan DIR Grants Approval for Lotus’ Acquisition of Alvogen US, Aiming 2025 Year-End Closing
- Investors12 November 2025
Lotus Pharmaceutical Reports Results for the Third Quarter and First Nine Months of 2025
- Investors10 November 2025
Lotus Reports October 2025 Revenue of NT$2,753 Million
- Investors09 October 2025
Lotus reports September 2025 Revenue of NT$1,214 Million
